Compare ALXO & HYPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALXO | HYPR |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.7M | 104.0M |
| IPO Year | 2020 | N/A |
| Metric | ALXO | HYPR |
|---|---|---|
| Price | $1.47 | $1.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $3.30 | $1.28 |
| AVG Volume (30 Days) | 255.4K | ★ 594.5K |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $10,591,000.00 |
| Revenue This Year | N/A | $5.17 |
| Revenue Next Year | N/A | $35.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.40 | $0.53 |
| 52 Week High | $2.27 | $2.22 |
| Indicator | ALXO | HYPR |
|---|---|---|
| Relative Strength Index (RSI) | 51.75 | 43.62 |
| Support Level | $1.29 | $0.85 |
| Resistance Level | $1.57 | $1.10 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 67.50 | 44.59 |
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.